EUVIMEDEUVIMED entdecken
Open Access

Understanding Enzalutamide‐Resistance Based on a Functional Single‐Cell Approach

Changhui Xue, Hyun-Kyung Ko iD, Kasen Shi, Janet Pittsenbarger, Lucien Vu Dao, Kaiyo Shi, Maximilian Libmann, Hao Geng, David Z Qian iD

The Prostate · 2025

DOI: 10.1002/pros.24895 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Prostate, 2025. Verfasst von Changhui Xue und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncological Sciences, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA. Hauptthemen laut MEDLINE: Phenylthiohydantoin, Drug Resistance, Neoplasm, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, This study is supported by NIH/NCI grants 5R01CA149253 and 5R01CA207377 to D.Z.Q..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Anti‐androgen or castration therapies are the mainstay treatment for metastatic prostate cancers (PCa). Although effective at first, androgen‐dependent PCa (ADPC) universally develops therapy resistance, thereby evolving into an incurable disease called castration‐resistant PCa (CRPC). Currently, mechanisms underlying the emergence of CRPC from ADPC are largely unclear.

Methods

We used single‐cell RNA‐sequencing (scRNA‐Seq) to determine the transcription heterogeneity of a therapy‐naïve ADPC cell line—LNCaP and how it responded to the anti‐androgen drug, enzalutamide. Based on the results, we used single‐cell/colony‐based cloning to isolate a pre‐enzalutamide cell subset, displaying low and/or no expression of androgen receptor (AR low/− ).

Results

We found that most LNCaP cells expressed enzalutamide‐target androgen receptor (AR+), while a small subpopulation (~10%) expressed low or no AR (AR low/− ). Gene set enrichment analysis (GSEA) revealed that AR + and AR low/− cells were enriched with significantly different gene expressions and signaling pathways. Unexpectedly, AR low/− cells displayed robust transcriptional response, including upregulations of genes and pathways involved in clinical CRPC. Next, we isolated AR low/− and AR + cells from enzalutamide‐naïve LNCaP cells and functionally confirmed the enzalutamide‐resistant phenotype of AR low/− cells in vitro and in xenograft models in vivo. Through xenograft‐based single‐nucleus RNA‐Seq, we further found that the AR low/− cells were selected, while the AR + cells were de‐selected in vivo by enzalutamide. Also, we found that the selection and expansion of AR low/− clone were recapitulated in another enzalutamide‐resistant cell model.

Conclusion

In summary, our single‐cell‐based sequencing and functional tests suggest a clonal selection and expansion model of enzalutamide resistance, in which the pretreatment AR‐low subpopulation is selected and expanded to confer treatment resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhenylthiohydantoinDrug Resistance, NeoplasmProstatic Neoplasms, Castration-ResistantNitrilesBenzamidesHumansSingle-Cell AnalysisMaleReceptors, AndrogenCell Line, TumorAnimalsMiceXenograft Model Antitumor Assays

Stichwörter der Autor:innen

androgen receptorcastration resistanceenzalutamideprostate cancersingle‐cell RNA‐Seq

Substanzen

enzalutamideNitrilesBenzamidesPhenylthiohydantoinReceptors, AndrogenAR protein, human

Autor:innen und Institutionen

  • Division of Oncological Sciences, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.

ORCID-Profile: Hyun-Kyung Ko, David Z Qian

Förderung

  • NCI NIH HHS
  • This study is supported by NIH/NCI grants 5R01CA149253 and 5R01CA207377 to D.Z.Q.

Zitieren

APA

Xue, C., Ko, H. K., Shi, K., Pittsenbarger, J., Vu Dao, L., Shi, K., Libmann, M., Geng, H., & Qian, D. Z. (2025). Understanding Enzalutamide‐Resistance Based on a Functional Single‐Cell Approach. The Prostate. https://doi.org/10.1002/pros.24895

Vancouver

Xue C, Ko HK, Shi K, Pittsenbarger J, Vu Dao L, Shi K, et al. Understanding Enzalutamide‐Resistance Based on a Functional Single‐Cell Approach. The Prostate. 2025. doi:10.1002/pros.24895

BibTeX
@article{Xue2025,
  author = {Xue, Changhui and Ko, Hyun-Kyung and Shi, Kasen and Pittsenbarger, Janet and Vu Dao, Lucien and Shi, Kaiyo and Libmann, Maximilian and Geng, Hao and Qian, David Z},
  title = {Understanding Enzalutamide‐Resistance Based on a Functional Single‐Cell Approach},
  journal = {The Prostate},
  year = {2025},
  doi = {10.1002/pros.24895}
}
Kostenlos starten →